Shares of Soleno Therapeutics Inc. (SLNO) are down over 20% from their 52-week high of $60.92, recorded last month, and trade around $47.
This clinical-stage biopharmaceutical company is developing novel therapeutics for the treatment of rare diseases. Its lead drug candidate is DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for treating Prader-Willi syndrome.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com